Template bleeding time and PFA-100® have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages:: comparative study in 148 patients

被引:108
作者
Quiroga, T
Goycoolea, M
Muñoz, B
Morales, M
Aranda, E
Panes, O
Pereira, J
Mezzano, D
机构
[1] Catholic Univ Chile, Sch Med, Dept Hematol Oncol, Santiago, Chile
[2] Catholic Univ Chile, Sch Med, Clin Lab, Santiago, Chile
[3] Roberto Rio Hosp, Pediat Hemaphilia Ctr, Santiago, Chile
关键词
PFA-100((R)); primary hemostasis; primary platelet secretion defects; von Willebrand disease;
D O I
10.1111/j.1538-7836.2004.00693.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives and patients: We compared the template bleeding time (BT) and closure time (CT) in the PFA-100(R) as screening tests in 148 consecutive patients With unequivocal mucocutaneous bleeding and positive family history. Exclusion criteria: drug intake, concomitant diseases including minor infections, low platelet Count, diseases of secondary hemostasis. Results: Type I von Willebrand disease (VWD-1) was diagnosed in 26 patients, primary platelet secretion defect (PSD) in 33, VWD-1 + PSD in nine, whereas 80 patients did not comply with the criteria for known hemostatic disorders (UD, unknown diagnosis). BT and CT were prolonged in 35.8% and 29.7% of all the patients, respectively (P = 0.23). Sensitivity increased to 48% if an abnormality of BT and/or CT was considered. Same comparisons for BT and CT in each diagnostic category were. respectively: 42 vs. 61.5% in VWD-1 (P = 0.18), 42 vs. 24% in platelet secretion defects (P = 0.11), 67 vs. 89% in VWD-1 + PSD (P = 0.50), and 27.5 vs. 15% in UD (P = 0.06). Conclusion: Both tests were relatively insensitive and not significantly different in detecting incoming patients with mucocutancous hemorrhages. In patients with VWD-1 the PFA-100(R) performed slightly better, whereas the opposite occurred in those patients with platelet secretion defects. In the UD group, both tests lost sensitivity, but the BT detected 1.8 times more patients than the PFA-100(R). Given the large proportion of undiagnosed bleeders and the overall low sensitivity of these tests, clinical decisions still rely on the medical history and etiological diagnosis of the bleeding disorder.
引用
收藏
页码:892 / 898
页数:7
相关论文
共 30 条
[1]  
ALLAIN JP, 1975, J LAB CLIN MED, V85, P318
[2]  
BUDDE U, 1990, THROMB HAEMOSTASIS, V63, P312
[3]  
BUNSCHOTEN EPM, 1988, THROMB HAEMOSTASIS, V59, P349
[4]  
BURNS ER, 1989, ARCH PATHOL LAB MED, V113, P1219
[5]   Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion [J].
Cattaneo, M ;
Lecchi, A ;
Agati, B ;
Lombardi, R ;
Zighetti, ML .
THROMBOSIS RESEARCH, 1999, 96 (03) :213-217
[6]  
Cattaneo M, 1999, THROMB HAEMOSTASIS, V82, P35
[7]   Inherited platelet-based bleeding disorders [J].
Cattaneo, M .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (07) :1628-1636
[8]  
Dean JA, 2000, THROMB HAEMOSTASIS, V84, P401
[9]   Clinical application of the PFA-100® [J].
Favaloro, EJ .
CURRENT OPINION IN HEMATOLOGY, 2002, 9 (05) :407-415
[10]   Utility of the PFA-100® for assessing bleeding disorders and monitoring therapy:: a review of analytical variables, benefits and limitations [J].
Favaloro, EJ .
HAEMOPHILIA, 2001, 7 (02) :170-179